NM922

NM922 is a novel small-molecule drug developed by NovoMedix that acts as a dual AMPK activator and mTOR inhibitor. It functions as a translation initiation inhibitor, targeting the mTORC1 and mTORC2 pathways to inhibit the phosphorylation of key downstream proteins such as p70 S6 kinase, 4E-BP1, Akt, and PI3 kinase. NM922 is being investigated for its therapeutic potential in triple-negative breast cancer (TNBC), where it demonstrates dual activity on both primary tumors and the tumor stroma. In cardiovascular applications, it attenuates cardiac fibrosis and preserves cardiac function by inhibiting fibroblast-to-myofibroblast transformation. The compound is also being explored for the treatment of arthrofibrosis (joint scarring) and has demonstrated good oral bioavailability in preclinical models.